Clinical trials: PET/CT, open to volunteers
Non-Small Cell Lung Cancer
68Ga-grazytracer PET/CT for Early Assessment of Response to Neoadjuvant Immunotherapy in Resectable NSCLC
The purpose of this study is to explore the effectiveness of 68Ga-grazytracer PET/CT in early evaluation of neoadjuvant immunotherapy response in resectable NSCLC.
- Trial name
- NCT06756217
- Testing
- 68Ga-grazytracer PET/CT
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Ruijin Hospital
Endometriosis
Use of a New Diagnostic Tool in the Detection and Characterization of Endometriosis Lesions
Diagnostic wandering is one of the characteristics of endometriosis due to great anatomical and clinical variability but also due to poorly relevant diagnostic examinations.
- Trial name
- ENDO-TEP (NCT07053982)
- Testing
- Preoperative [18F]-FES PET/CT Imaging and Estrogen Receptor Expression Analysis in Endometriosis Surgery
- Where
- France
- Volunteers
- 20 people
- Sponsor
- University Hospital, Toulouse
Malignant Neoplasm
68Ga-JH12 PET/CT: Dosimetry and Biodistribution Study
68Ga-JH12 is a novel radiotracer targeting C-X-C motif chemokine receptor 4 (CXCR4). In this study, we observed the safety, biodistribution, and radiation dosimetry of 68Ga-JH12 in patients with different types of cancer.
- Trial name
- NCT06688188
- Testing
- 68Ga-JH12
- Where
- China
- Volunteers
- 5 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Localized Prostate Carcinoma, Oligometastatic Prostate Carcinoma
Accuracy of 18F-rhPSMA-7.3 PET/ MRI for Prediction of Lymph Node Metastasis in Localized High-Risk Prostate Cancer
This clinical trial evaluates the use of an imaging scan (18F-rhPSMA-7.3 positron emission tomography [PET]/magnetic resonance imaging [MRI]) for identifying patients who are at risk of having their disease spread to the lymph…
- Conditions
- Localized Prostate Carcinoma, Oligometastatic Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8
- Trial name
- NCT06389786
- Testing
- Bilateral Pelvic Lymph Node Dissection, Biospecimen Collection, Bone Scan
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Mayo Clinic
Pyrexia
Comparison of FDG-PET/CT and CECT-CAP as Upfront Imaging Modality for the Diagnosis of Pyrexia of Unknown Origin
Pyrexia of unknown origin (PUO) remains one of the most challenging diagnostic problems in modern medicine. Despite advances in laboratory diagnostics, microbiological techniques, imaging modalities, and molecular testing, a…
- Trial name
- CET-PET-PUO (NCT07816783)
- Testing
- FDG-PET, CECT, Standard care of therapy
- Where
- India
- Volunteers
- 132 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Malignancy
Application of 18F-PSMA PET / CT Imaging in Prostate Specific Membrane Antigen Positive Tumor
In this study, Al18F-PSMA-BCH PET/CT will be performed in patients with prostate specific membrane antigen positive tumor, to evaluate the tumour detection efficacy of Al18F-PSMA-BCH PET/CT.
- Trial name
- NCT05761366
- Testing
- Al18F-PSMA-BCH PET/CT
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
SSTR-related Disease, Tumor
Somatostatin Receptor PET/CT in SSTR-Related Disease Patients
To evaluate the potential usefulness of 68Ga/18F-TATE/JR11/LM3 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various SSTR-related disease patients.
- Conditions
- SSTR-related Disease, Tumor, Positron Emission Tomography, Metastasis
- Trial name
- NCT06690957
- Testing
- 68Ga/18F-TATE/JR11/LM3
- Where
- 3 sites in China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Tianjin Medical University
Tumor, Solid Tumor
Trophoblast Cell-Surface Antigen 2 (Trop-2) Targeted PET/CT in Recurrent and Metastatic Thyroid Cancer
In this study, we comprehensively evaluated the clinical utility of Trop2 PET/CT (68Ga-MY6349 PET/CT) imaging for detecting recurrent and metastatic thyroid cancer, and the results were compared with those of 68Ga-FAPI PET/CT.
- Conditions
- Tumor, Solid Tumor, Thyroid Cancer
- Trial name
- NCT07753499
- Testing
- Compared the diagnostic performance of 68Ga-MY6349 PET/CT with 68Ga-FAPI PET/CT
- Where
- China
- Volunteers
- 120 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Non Small Cell Lung Cancer
Molecular Imaging of FAP Expressing Cancer-associated Fibroblasts in NSCLC Treated With Immune-checkpoint Inhibitors
Evaluation of the relation between baseline fibroblast activation protein (FAP) expression based on Ga-FAPI uptake with patient outcome among NSCLC patients receiving immunotherapy for recurrent/metastatic disease.
- Trial name
- LIFE (NCT06107608)
- Testing
- FAPI PET/CT
- Where
- Belgium
- Volunteers
- 58 people
- Sponsor
- Jules Bordet Institute
Hepatocellular Carcinoma (HCC), Glypican-3
GPC3-Targeted PET/CT in Hepatocellular Carcinoma
The objective of the study is to evaluate the diagnostic value of GPC3-targeted PET/CT in patients with suspected or histologically/clinically confirmed hepatocellular carcinoma, and to compare with contrast-enhanced MRI.
- Conditions
- Hepatocellular Carcinoma (HCC), Glypican-3, GPC3-targeted PET/CT
- Trial name
- NCT07677774
- Testing
- GPC3-targeted PET/CT
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Thyroid Cancer
The Value of 68Ga-FAPI PET/CT in Preoperative Evaluation of Thyroid Cancer with Lymph Node Metastases
This study aims to investigate the value of 68Ga-FAPI in the preoperative evaluation of thyroid cancer of different pathologic types.
- Trial name
- NCT06730529
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Ruijin Hospital
PET-CT, Lymphoma
PET-CT in Lymphoma Among the Eldery
This study investigates PET-CT imaging patterns and metabolic parameters in elderly patients (≥60 years) diagnosed with lymphoma, aiming to enhance diagnostic accuracy and prognosis using 18F-FDG PET/CT scans.
- Conditions
- PET-CT, Lymphoma, Elderly, Metabolic Parameters
- Trial name
- NCT07259941
- Volunteers
- 63 people
- Sponsor
- Assiut University
Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma
PET/CT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung Cancer
This study investigates the changes in positron emission tomography (PET)/computed tomography (CT) imaging scans during chemoimmunotherapy and radiation therapy treatment in patients with stage IV non-small cell lung cancer.
- Conditions
- Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
- Trial name
- NCT04151940
- Testing
- Positron Emission Tomography, Computed Tomography, Chemotherapy
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of Washington
Indolent B-Cell Non-Hodgkin Lymphoma
Ga-68-CXCR4 PET/CT in Indolent B-cell Lymphoma
This study explores the efficacy of Ga-68-PentixaFor PET/CT in detecting, assessing treatment response, and monitoring the risk of aggressiveness in indolent B-cell lymphoma.
- Trial name
- PentixaFor (NCT06461182)
- Testing
- Ga-68-CXCR4
- Where
- Taiwan
- Volunteers
- 15 people
- Sponsor
- Koo Foundation Sun Yat-Sen Cancer Center
Intermediate Risk Prostate Cancer, High Risk Prostate Cancer
Androgen-responsive POSLUMA-guided Intra-prostatic Boost
This research study is for men with intermediate- or high-risk prostate cancer who are planning to receive hormone therapy and radiation treatment.
- Conditions
- Intermediate Risk Prostate Cancer, High Risk Prostate Cancer, Prostate Cancer
- Trial name
- ARPEGGIO (NCT07393867)
- Testing
- PSMA PET/CT, Androgen Deprivation Therapy (ADT) +/- bicalutamide, Stereotactic Body Radiation Therapy (SBRT) +/- focal microboost
- Where
- 4 sites in United States
- Volunteers
- 23 people
- Sponsor
- Martin T. King, MD, PhD
Metastatic Colorectal Cancer
18FFDG PET/CT for Early Evaluation of Chemotherapy Efficacy in Metastatic Colic Adenocarcinoma
The metastatic colo-rectal cancer (especially with hepatic metastatic lesions, but also peritoneal or pulmonary lesions) is a major public health issue, because of its frequency, the heavy treatments and the cost of new…
- Trial name
- TEP-PREDICT (NCT05531045)
- Testing
- PET/CT
- Where
- France
- Volunteers
- 222 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8
Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial
This phase II trial studies how well a short course of androgen deprivation therapy (ADT) with relugolix works in increasing expression of prostate-specific membrane antigen (PSMA) and improving diagnostic imaging with PSMA…
- Conditions
- Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
- Trial name
- NCT07025369
- Testing
- Biospecimen Collection, Computed Tomography, Flotufolastat F-18 Gallium
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic
Low Grade Glioma, Glioblastoma
Positron Emission Tomography/Computed Tomography (PET/CT) Imaging in Patients Diagnosed With a Glioma
The goal of this clinical trial is to evaluate Positron emission tomography/computed tomography (PET/CT) imaging with the radiotracer 1-(2-[18F]fluoroethyl)-l-tryptophan ([18F]FETrp) in patients diagnosed with a glioma.
- Trial name
- NCT07735819
- Testing
- Minocycline 200mg/day, [18F]FETrp PET/CT
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Uterine Cancer
[18F]FES PET/.CT in Uterine Cancer
Women with known or suspected recurrent or metastatic uterine cancer may be eligible for this study. Patients may participate in this study if they are at least 18 years of age, most participants will be receiving care at the…
- Trial name
- NCT05916196
- Testing
- 18F-Fluoroestradiol
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Urologic Neoplasms, Urogenital Neoplasms
CD70-targeted immunoPET Imaging of Kidney Cancer
The aim of this study is to establish and optimize the [18F]RCCB6 PET/CT imaging method, and its physiological and pathological distribution characteristics, on the basis of which the diagnostic efficacy of the above imaging…
- Conditions
- Urologic Neoplasms, Urogenital Neoplasms, Kidney Neoplasms, Neoplasms
- Trial name
- NCT06680089
- Testing
- [18F]RCCB6
- Where
- China
- Volunteers
- 300 people
- Sponsor
- RenJi Hospital